As Legend Biotech became…
As Legend Biotech became profitable, the company is navigating Carvykti’s [...]
With its reserves depleted, a debt…
With its reserves depleted, a debt payment due in four [...]
As the massive market for GLP-1…
As the massive market for GLP-1 weight-loss drugs continues to [...]
AstraZeneca’s newly approved…
AstraZeneca’s newly approved blood pressure drug Baxfendy does not clear [...]
Abbott is again tapping into the…
Abbott is again tapping into the competitive spirit of Big [...]
Roughly a year and a half after…
Roughly a year and a half after the approval of [...]
Legend Biotech’s interim CEO, Alan…
Legend Biotech’s interim CEO, Alan Bash, discusses competition from T-cell [...]
Shortly after initiating a…
Shortly after initiating a separate recall tied to mislabeled pain [...]
Snapchat is courting pharma…
Snapchat is courting pharma marketers with a new ad format [...]
Despite their divergent…
Despite their divergent second-quarter performance against consensus estimates, BridgeBio and [...]